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Abstract 
Aim: The use of platelets as biomaterials has gained intense research interest. However, 
the mechanisms regarding platelet-mediated skeletal myogenesis remain to be established. 
The aim of this study was to determine the role of platelet releasate in skeletal myogenesis 
and muscle stem cell fate in vitro and ex vivo respectively. 
 
Methods: We analysed the effect of platelet releasate on proliferation and differentiation of 
C2C12 myoblasts by means of cell proliferation assays, immunohistochemistry, gene 
expression and cell bioenergetics. We expanded in vitro findings on single muscle fibres by 
determining the effect of platelet releasate on murine skeletal muscle stem cells using 
protein expression profiles for key myogenic regulatory factors.  
 
Results: TRAP6 and collagen used for releasate preparation had a more pronounced effect 
on myoblast proliferation versus thrombin and sonicated platelets (P<0.05). In addition, 
platelet concentration positively correlated with myoblast proliferation. Platelet releasate 
increased myoblast and muscle stem cell proliferation in a dose-dependent manner, which 
was mitigated by VEGFR and PDGFR inhibition. Inhibition of VEGFR and PDGFR ablated 
MyoD expression on proliferating muscle stem cells, compromising their commitment to 
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differentiation in muscle fibres (P<0.001). Platelet releasate was detrimental for myoblast 
fusion and affected differentiation of myoblasts in a temporal manner. Most importantly we 
show that platelet releasate promotes skeletal myogenesis through the PDGF/VEGF-Cyclin 
D1-MyoD-Scrib-Myogenin axis and accelerates skeletal muscle regeneration after acute 
injury. 
 
Conclusion: This study provides novel mechanistic insights on the role of platelet releasate 
in skeletal myogenesis and set the physiological basis for exploiting platelets as biomaterials 
in regenerative medicine. 
 
Key words: growth factors, platelet releasate, platelet-rich plasma, regeneration, skeletal 
muscle, satellite cells 
 
Introduction  
Skeletal muscle is a remarkably plastic tissue with a strong capacity to regenerate after 
injury due to a small population of skeletal muscle stem cells, termed satellite cells. These 
muscle stem cells are typically quiescent, but become activated upon myofibre injury, 
proliferate and either return to quiescence or differentiate to support regeneration 1. 
However, this regenerative ability typically comes at a cost, such as incomplete functional 
recovery, stiffness, excessive inflammation or fibrosis 2-4. There is currently an increasing 
interest in the field of skeletal muscle regenerative research. This is driven by the increasing 
prevalence of injuries in both office and sporting vocations, a lack of effective treatments for 
myopathies, neuromuscular disease and sarcopenia, and finally, an intense interest in 
preventing skeletal muscle atrophy in microgravity 5-8. Taking all these factors into 
consideration, skeletal muscle injuries, myopathies and research into these areas are of 
great economical interest to both governmental bodies and private-sector industries alike. At 
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present, conventional treatments to musculoskeletal injuries include rest, ice, compression 
and elevation (RICE), nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy 9. 
 
Lacking evidence for the effectiveness of RICE and NSAIDs leave the field of skeletal 
muscle regeneration somewhat redundant 10, 11. Autologous platelet rich plasma (PRP; an 
autologous biomaterial where platelets are re-suspended in plasma) treatment has emarged 
as an alternative to the above-mentioned methods. This is due to the cost, ease of 
availability to numerous cytokines and growth factors (such as IGF-1, VEGF and PDGF 
contained in the alpha-granules of the platelets) to the targeted area, acting as biomaterials 
to regulate cell cycle, promote wound healing and stimulate regeneration 12-15. Growth 
factors and cytokines are essential components of the early inflammatory response and 
subsequent successful tissue regeneration 16. However, there are inconsistencies in the 
literature as to whether PRP proves beneficial in skeletal muscle regeneration 13, 17. It has 
been speculated that methodological variability may account for the observed discrepancies 
among studies on the effectiveness of PRP in wound healing and tissue regeneration 13, 18, 
19. Another leading proposition for the debatable effects of PRP on skeletal muscle 
regeneration may be the abundance of cytokines that can induce fibrosis, such as 
transforming growth factor beta-1 (TGF-β1) 3, 4, 20-22. 
 
Data from clinical studies on the effectiveness of PRP-based applications for skeletal muscle 
regeneration is limited. Therefore, the need for a better understanding of the effects of 
platelets on skeletal muscle regeneration is necessary. Recent data suggest that platelet 
releasate, a refined suspension of growth factors released from aggregated platelets, where 
the platelet cellular-debris is removed, can be used as an alternative method to using PRP 
for treating musculoskeletal regeneration 15, 17, 23-25.  
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Therefore, the aim of this study was: i) to determine the impact of methodological variability 
in platelet preparations on skeletal myogenesis, ii) dissect the effect of platelet releasate on 
myoblast and muscle stem cell’s myogenic potential in vitro and ex vivo respectively and iii) 
to define the molecular mechanisms of platelet releasate in regulating muscle stem cell fate 
and recruitment. Briefly, we show here that platelet releasate is capable to drive myoblast 
and muscle stem cell proliferation and differentiation both in vitro and ex vivo. This effect is 
mediated by the PDGF/VEGF pathway that promotes muscle stem cell commitment to 
differentiation and ultimately enhances myogenesis. The findings of this study set the basis 
for exploiting platelets as biomaterials to promote tissue regeneration in future studies. 
 
Results 
The effect of platelet agonists and centrifugation speed during releasate preparation 
and dosage of releasate on C2C12 myoblast proliferation. There is currently large 
controversial evidence on the role of PRP in tissue regeneration 13, 17-19, 26, 27. We therefore, 
aimed to determine the effect of methodological variations during platelet releasate 
preparation on C2C12 myoblast proliferation. To this aim, C2C12 myoblasts were cultured 
for 24 hours in serum-free media (SF) supplemented with releasate (R) derived from either 
collagen, TRAP6 (a PAR1 agonist), or thrombin-activated platelets, which were centrifuged 
at different speeds after stimulation (i.e. 1400, 5500 and 9500g) (Figure 1A-C and S. 
Figure 1). These were compared to cells incubated with lysates from sonicated platelets (i.e. 
S.L.). Treatment of cells with 10% releasate resulted in significantly increased cell 
proliferation (i.e. 32-55%) independent of the agonist and centrifugation speed as compared 
to SF-treated cells (i.e. 5%; negative control). C2C12 myoblast proliferation in response to 
treatment with TRAP6- and collagen-activated releasate was comparable to cells treated 
with 20% growth medium (GM, containing 20% FBS; positive control). However, the highest 
percentage for myoblast proliferation amongst groups was found for PAR1-activated platelet 
releasate independent of centrifugation speed. Obtaining platelet lysates by sonication did 
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not show any additional advantage on myoblast proliferation as compared to releasate 
activated with either TRAP6 or collagen. Of note, collagen-, TRAP6- and thrombin-activated 
platelets had similar levels of aggregation and total protein (mg mL-1) (S. Figure 2, Figure 
1D respectively). Taken together, these findings suggest that growth factors from thrombin-
activated or sonicated platelets improve C2C12 myoblast proliferation to a lesser extent than 
collagen- or PAR1-activated platelet releasate, while the final centrifugation speed during 
platelet preparation does not appear to play an important role. We therefore, continued using 
TRAP6 at 9500g to obtain platelet releasate for all subsequent experiments. The 
proliferative effect using this method of platelet preparation was supported with Ki-67 and 
cell viability experimentation (S. Figure 3).  
 
We next determined the dose-response of platelet releasate on C2C12 cell proliferation. 
Cells were treated with 10-, 20- or 30% releasate for 24 hours. Administration of 10-30% 
releasate resulted in significant myoblast proliferation compared to serum free (SF) 
conditions (50-62% vs. 5% respectively; Figure 1E). In addition, 20- and 30% releasate 
exhibited a higher proliferative effect on murine myoblasts as compared to the 10% 
releasate group (Figure 1E). These data are indicative of a dose-dependent effect of 
releasate on myoblast proliferation. 
 
Human releasate has a stronger proliferative effect on C2C12 cells than murine 
releasate. We also established the effect of human and mouse platelet releasate on 
myoblast proliferation. From an ethical point of view, human platelet releasate is more 
readily available without the need for murine sacrifice 28. However, the species-specific 
variability of murine versus human platelet releasate treatment on murine C2C12 myoblast 
proliferation was investigated. We sought to establish whether using the same concentration 
of platelets (2.5x108 mL -1; physiological levels of platelets in human blood) of 10% murine 
platelet releasate (Mouse R) on murine cells would yield better proliferation than 10% human 
platelet releasate (Human R) due to species homology. Serum-free conditions and 20% FBS 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
(20% GM) were used as negative and positive controls respectively. Mouse releasate was 
found to be significantly less affective by 10% in promoting cell division than human 
releasate (Figure 1F). This may be accountable to the fact that nominal levels of platelets in 
murine blood are 3.5-7 times higher than human blood (i.e. 12.5x108 mL-1; physiological 
levels of platelets in mouse versus 2.5x108 mL -1 in human blood). In addition, the platelets of 
mice are considerably smaller in size (2-4 times) than human platelets29. Since murine 
platelets do not express the PAR-1 receptor, we used collagen as a platelet agonist 30. 
Correcting for these variables may optimise the proliferative capacity of murine releasate.  
 
Releasate from physiological platelet concentrations is beneficial for myoblast 
proliferation. We next aimed to explore the effect releasate from varying platelet 
concentrations on myoblast proliferation. To address this, platelet concentrations of 0.1x108 
– 10x108 platelets mL-1 from human blood were used (Figure 2A). Releasate prepared from 
sub-physiological levels of platelets (i.e. 0.1-1x108 platelets mL-1) resulted in diminished 
myoblast proliferation compared to cultures supplemented with growth medium (GM; 10% 
FBS, positive control). However, releasate from physiological platelet concentrations (i.e. 
2.5x108 platelets mL-1) resulted in significantly higher myoblast proliferation compared to 
releasate from sub-physiological platelet concentrations and serum free conditions, which 
was similar to the growth medium (GM) group. There was a positive correlation between the 
platelet concentration used for releasate preparation and myoblast proliferation (S. Figure 
4). Interestingly, releasate from supra-physiological levels of platelets exhibited additional 
effects on myoblast proliferation by approximately 30% compared to the physiological 
concentration. These findings indicate that the supra-physiological levels of platelets have a 
stronger effect on the proliferative capacity of the C2C12 myoblasts. 
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The effect of releasate on gene and protein expression patterns of C2C12 myoblasts. 
We next applied releasate from physiological levels of human platelets (2.5x108 platelets mL-
1) on proliferating C2C12 myoblasts for 48 hours and we measured gene expression by 
quantitative real-time RT-PCR. There were significantly higher mRNA levels (p<0.001) for 
Vegfα165, Vegfr1, Pdgfα, Pdgfβ (growth factors and their receptors involved in myogenesis), 
Pax7, Myf5 and Myod (myogenic regulatory factors) and Prmt1 (a regulator of muscle stem 
cell fate) in response to releasate treatment in serum-free or serum-rich conditions 
compared to non-releasate controls (i.e. SF and GM respectively). We observed significantly 
lower (p<0.01) mRNA levels for Igf1 (growth factor involved in myogenic differentiation) in all 
groups as compared to the SF group. Transcript levels of the Igf1r and Pdgfαr receptors 
were unchanged between groups. Pdgfβr mRNA levels were upregulated by releasate in the 
GM group only (Figure 2B). mRNA levels for the DNA repair genes Ogg1 (8-Oxoguanine 
glycosylase), Gadd45g (Growth arrest and DNA-damage-inducible protein 45 gamma) and 
Parp1 (Poly [ADP-ribose] polymerase 1) were increased for all groups versus the SF group 
(S. Figure 5). Gene expression of neurotrophins and their receptors (i.e. Nerve growth 
factor; Ngf, Brain-derived neurotrophic factor; Bdnf, Neurotrophin-3; Ntf-3 and their receptors 
Tropomyosin receptor kinase A, B and C; TrkA, TrkB and TrkC respectively) was not 
affected by the administration of releasate on proliferating myoblasts (S. Figure 5). Platelet 
releasate also induced higher PDGFB and VEGF protein levels in proliferating C2C12 
myoblasts (Figure 2C and S. Figure 6). These findings suggest that platelet releasate 
regulates PDGF and VEGF mRNA and protein expression. 
 
Growth factors in platelet releasate. We next aimed to get insights into the levels of 
relevant growth factors contained in platelet releasate. For this purpose, we stimulated 
washed platelets from human blood with agonists that induce platelet aggregation and 
degranulation [i.e. TRAP6 (a PAR1 agonist) or collagen] or left the platelet suspension 
untreated. The levels of 32 biomarkers involved in cell proliferation and differentiation were 
measured. All biomarkers were increased several-fold in TRAP6 and collagen induced 
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releasate compared to unstimulated platelets (Figure 3). In particular, we found that 
between unstimulated and stimulated (Collagen and TRAP6) groups, two clusters based on 
relative heatmap intensity have emerged. One cluster with a moderate increase including 
uPA, IL-18, Angiopoietin-2, Follistatin, IGFBP-1, Endoglin, IL-6, sCD40L, PLGF, TGF-α and 
TNF-α and a second cluster with >10-fold increase including VEGF-A, -C and -D, SCF, 
PDGF, EGF, sFASL, HGF, sVEGFR-1, -2, sTIE2, FGF and sEGFR. Lower levels of some 
biomarkers were detectable in unstimulated platelets. Published evidence regarding the role 
of these biomarkers in myoblast proliferation and differentiation is summarised in 
supplementary Table 1. 
 
Platelet releasate drives myoblast proliferation through PDGF and VEGF. Given the 
above observations that mRNA and protein levels of PDGF and VEGF are increased in 
proliferating myoblasts (Figure 2), as well as their abundance in the releasate (Figure 3), 
we reasoned that these growth factors may be governing cell proliferation, as shown when 
individually targeted 31, 32. To further investigate this notion, we used low, medium and high 
doses of VEGFR or PDGFR Inhibitors with or without releasate to assess C2C12 cell 
proliferation (Figure 4A, B). Treatment with VEGFR and PDGFR inhibitors resulted in a 
dose-dependent attenuation of myoblast proliferation in groups treated with platelet 
releasate (Figure 4B).  A similar trend was observed under serum free (SF) conditions with 
the VEGFR and PDGFR inhibitors. Additionally, VEGFR and PDGFR inhibition 
compromised C2C12 proliferation under serum-rich (i.e. growth medium) conditions as 
indicated by decreased total cellular number (S. Figure 7). Taken together, these data 
suggest that myoblast proliferation is, at least in part, driven by the VEGF and PDGF growth 
factors contained in the platelet releasate. 
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Temporal effects of platelet releasate on myoblast differentiation. It is known that 
growth factors contained in platelet granules such as Hepatocyte growth factor (HGF), TGF-
β1, Insulin-like growth factor 1 (IGF-1), Soluble Angiopoietin-1 receptor (sTIE-2), 
Angiopoietin-2 and Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) are 
beneficial for myotube fusion 3, 15, 22, 33, 34. Therefore, we next hypothesised that releasate 
would be beneficial in C2C12 myoblast differentiation into myotubes. To test this hypothesis, 
we assessed myotube differentiation in response to releasate administration either i) during 
the proliferative phase (day 0-2, GM+R;DM) or ii) throughout the proliferation and 
differentiation (day 0-9, GM+R:DM+R). We found a significant decrease in myogenic fusion 
and differentiation mRNA (Myogenin, Mhc1, Mhc2a, Mhc2b, Acta1, Tmem8c, Bex1 and Igf1) 
for the continuously added releasate group (GM+R;DM+R) versus the other two groups 
(GM:DM and GM+R;DM; which were non-significantly different for all expression). Myod, 
Pgdfβ and Vegfα165 mRNA expression was increased in all groups that had received 
releasate treatment. Pax7 mRNA expression was decreased for GM+R;DM and increased 
for GM+R;DM+R versus the GM;DM positive control group (Figure 5A). Strikingly, 
continuous administration of releasate during day 0-9 resulted in a robust inhibition of 
myoblast differentiation as shown by impaired myofusion, myotube number, myogenin 
expression, myotube length and myotube thickness with increased nuclei number. 
Subsequently, we asked whether platelet releasate improves myotube terminal 
differentiation when administered after the initiation of myoblast fusion (days 5-12, 
GM;DM+R.D5-12). We found that addition of releasate during terminal differentiation 
resulted in significantly increased total nuclear number, myotube number and myogenin 
expression without affecting the myofusion index or the myotube length and thickness 
(Figure 5B). Taken together, these findings suggest that continuous administration of 
releasate causes myoblasts to fail exiting the proliferative phase and has detrimental effects 
on myotube formation. Conversely, administration of platelet releasate after the initiation of 
myotube formation (i.e. terminal differentiation) is beneficial for myoblast differentiation. 
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PDGFR and VEGFR inhibition reduces myoblast differentiation. To gain mechanistic 
insights into the role of releasate on myoblast differentiation, we treated differentiating 
myoblasts with PDGFR and VEGFR inhibitors with or without platelet releasate (Figure 6A). 
We found that PDGFR inhibition reduced the total nuclei number, myogenin expression and 
total myotube number in cultures with or without platelet releasate. Similarly, VEGFR 
inhibition during myoblast differentiation resulted in decreased total nuclei number, 
myogenin expression and myotube number in cultures with or without platelet releasate 
(Figure 6B-C). These results indicate that PDGF and VEGF contained in releasate both are 
important for terminal myoblast differentiation. 
 
Platelet releasate increases myofibre stem cell commitment to differentiation through 
VEGF and PDGF in a dose-dependent manner. We next sought to determine if platelet 
releasate affected muscle stem cell expression profiles by using the single fibre ex vivo 
model. Immunohistochemical detection of Pax7+ve/MyoD-ve, Pax7+ve/MyoD+ve and Pax7-
ve/MyoD+ve cells identified quiescent, activated/proliferating and committed-to-differentiation 
muscle stem cells, respectively (Figure 7A). Platelet releasate added 1-3 times (x) with 
media change within 48 hours of culture resulted in a dose-dependent increase of Pax7-
ve/MyoD+ve cells compared to control (i.e. either serum free or fibre media conditions; Figure 
7B). For example, treatment of fibres with platelet releasate x3 resulted in a 300-400% 
increase of Pax7-ve/MyoD+ve cells in either serum free or fibre media (i.e. serum rich) 
conditions, indicating that platelet releasate increased muscle stem cell commitment to 
differentiation. Furthermore, administration of releasate three times (x3) during a 48-hour 
culture induced a 50-100% increase in committed stem cells (i.e. Pax7-ve/MyoD+ve) as 
compared to a single addition of platelet releasate (x1). The commitment index, defined as 
the number of Pax7-ve/MyoD+ve cells per single fibre, was increased with releasate addition 
compared to serum free conditions and releasate supplemented with fibre medium had an 
additional cumulative effect (Figure 7C). Interestingly, inhibition of the VEGF and PDGF 
receptors independently reversed the effect of releasate on both the number of committed 
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stem cells (i.e. Pax7-ve/MyoD+ve) to control levels (i.e. fibre media) as well as the total stem 
cell number to serum free conditions (Figure 7D). In an attempt to identify key downstream 
factors involved in muscle stem cell progression, we targeted Cyclin D1 and Scrib, which 
have been acknowledged as two important regulators of cell cycle and muscle stem cell fate 
respectively 24, 35. We found that platelet releasate resulted in a significant co-localisation of 
Cyclin D1 and Scrib with MyoD on muscle stem cells respectively, as well as a robust 
expression in proliferating C2C12 cells (Figure 8A-C and S. Figure 8). Ultimately, 
administration of platelet releasate on single fibres resulted in significantly higher muscle 
stem cell progeny independent of the use of serum in culture (i.e. SF and FM groups; Figure 
8D). Collectively, these data suggest that use of platelet releasate has a powerful effect on 
driving muscle stem cell commitment to differentiation and similar to C2C12 cells, the effects 
of releasate are mediated by the VEGF and PDGF pathways through cell cycle and cell fate 
regulation.  
 
Platelet releasate increases the total number of Myogenin+ve muscle stem cells and 
clusters per fibre. We followed up single myofibre cultures at 72 hours, where muscle stem 
cell progeny is expected to have differentiated to give rise to new myonuclei driven by high 
expression of myogenin 1. We found significantly increased Pax7-ve/Myogenin+ve cells in the 
releasate group as compared to serum free conditions, without any change in the relative 
expression patterns among groups (Figure 9A-B). The relative expression of 
Pax7+ve/Myogenin-ve cells (i.e. quiescent muscle stem cell pool) was not affected by the use 
of releasate, however was significantly increased between the FM and SF group. In addition, 
the total progeny stem cell number and the number of cell clusters per fibre were 
significantly higher in the fibre media and platelet releasate groups as compared to serum 
free media (Figure 9B). These data provide convincing evidence that the use of platelet 
releasate is beneficial for muscle stem cell differentiation ex vivo. Crucially, the normalised 
standardised rank curves illustrating the distribution of total muscle stem cell progeny 
number per myofibre were similar between the fibre medium (FM) and releasate (R) groups 
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as compared to serum free (SF) conditions after 48- and particularly 72- hours in culture. 
Furthermore, regression analysis correlating 48-hour and 72-hour muscle stem cell progeny 
numbers revealed different gradient values (i.e. slopes) indicating the muscle stem cell 
proliferation rates were different between SF cultures versus FM and releasate conditions 
(Figure 9C). These results suggest that the muscle stem cells that developed under the 
influence of releasate treatment retained their normal capacity to proliferate. Taken together, 
these findings suggest that platelet releasate promotes myogenesis to a similar extent as 
found for standard serum-rich cultures. 
 
Platelet releasate increases mitochondrial respiration of C2C12 myoblasts and 
skeletal muscle stem cells. Since mitochondria play a central role in the regulation of cell 
proliferation, we aimed to determine whether the use of platelet releasate affects the 
bioenergetic capacity of C2C12 myoblasts and muscle stem cells, by measuring the OCR 36, 
37. We found significantly increased OCR in C2C12 myoblasts under serum free conditions 
but no change in serum rich cultures (Figure 10A). Conversely, we found significantly higher 
spare respiratory capacity in muscle stem cells supplemented with platelet releasate in 
either serum-free or -rich conditions (Figure 10B). These data indicate that platelet 
releasate robustly affects the bioenergetics of muscle stem cells. 
 
Platelet releasate accelerates regeneration of skeletal muscle following acute damage 
with cardiotoxin. Having shown that platelet releasate had a profound effect on myoblast 
prefiltration and differentiation, we next examined its impact on the regeneration of adult 
mouse skeletal muscle, a process that is dependent on the generation of muscle precursors 
and their differentiation from the resident muscle stem cells. To this end the impact of 
platelet releasate was determined on muscle that has been acutely damaged using 
cardiotoxin (CTX) which causes muscle fibre necrosis, followed by macrophage-mediated 
debris clearance. Subsequent  formation of new muscle fibres originates from the progeny of 
satellite cells, which undergo proliferation, differentiation and fusion. Newly formed 
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regenerating muscle fibres were identified by their expression of embryonic myosin heavy 
chain (eMHC). We found that generation of newly formed fibres was significantly enhanced  
(P<0.001) in mice that had been treated with releasate compared to those that received PBS 
(Figure 11A). Furthermore, we found a profound impact of platelet releasate on the 
clearance of dead and dying fibres. The number and size of dying fibres (identified through 
the infiltration of IgG into fibres) present at 5 days after CTX damage in PBS-treated mice 
was significantly higher than those treated with platelet releasate (P<0.001, Figure 11B).  
These results show that platelet releasate promotes muscle regeneration by acting not only 
on muscle cells but possibly other components of the regeneration process. 
 
Discussion 
Platelet-based applications have gained much attention recently as an effective way to 
promote muscle regeneration reviewed by us and others 13, 18, 19. However, data are 
inconsistent and we have currently a limited understanding of the molecular events that 
govern skeletal myogenesis using platelet-based products as biomaterials 4, 17, 23. Due to 
largely inconsistent protocols in platelet preparation, we hypothesised here that 
methodological variables such as platelet agonists, final centrifugation speed and platelet 
count may be crucial in determining experimental outcomes among studies 3, 24, 38, 39. 
Therefore, we determined the effect of platelet agonists and final centrifugation speed and 
species-of-origin during releasate preparation on C2C12 myoblast proliferation. We found 
increased myoblast proliferation in response to releasate administration, which is in line with 
previously published data on the use of platelet releasate 20, 23, 24, 38, 40. 
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However, our data also suggest that platelet releasate from collagen and TRAP6, two widely 
used platelet agonists, have a stronger effect on myoblast proliferation as compared to 
thrombin or mechanically lysed platelets by sonication, independent of the final 
centrifugation speed used. This finding may be explained by possible detrimental effects of 
proteases on releasate growth factors, since thrombin itself is a serine protease, as well as 
digestive enzymes released in the ablation of sonicated platelets 41, 42. In addition, the use of 
10-30% of releasate resulted in a dose-dependent increase of myoblast proliferation, 
possibly due to higher amounts of releasate components. Since human platelet releasate 
was more powerful at promoting myoblast proliferation than mouse releasate, we used 
human releasate for all of the subsequent experiments. Platelet concentration was 
previously recognised as a potentially important variable for the diverse and conflicting data 
of PRP or releasate on tissue regeneration13, 43. Our data indicate that there is a linear 
relationship between platelet concentrations used for the production of releasate and 
myoblast proliferation and have to be taken into consideration in future studies. Collectively, 
despite a positive role of platelet releasate on myoblast proliferation, our data suggest that 
methodological variations such as: i) platelet agonists, ii) amount of releasate administered, 
iii) species of platelet origin and iv) platelet concentration may account for some of the 
discrepancies among studies. In order to be consistent with the amount of releasate used in 
several previous studies, we used physiological levels of platelets for the production of 
releasate in all the subsequent experiments 3, 12, 20, 23, 44. 
 
We next sought to determine the effect of releasate on myoblast gene and protein 
expression for factors known to regulate myogenesis. Gene and protein expression data 
from proliferating C2C12 myoblasts revealed a consistent significant increase in PDGF and 
VEGF in response to human releasate as compared to serum free (control) conditions. The 
physiological effect of PDGF on cell growth and C2C12 myoblast proliferation has been 
recognised previously45, 46. In fact, PDGF is found as homodimers of AA, BB, CC and DD or 
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a heterodimer of AB isoforms. Although PDGF-AA and PDGF-AB have little or no effect on 
myogenic proliferation and differentiation, it has been shown that PDGF-BB promotes 
muscle stem cell proliferation but inhibits differentiation 47-49. In turn, VEGF165α has been 
shown to enhance C2C12 myoblasts migration and exhibit anti-apoptotic effects 50. Higher 
mRNA levels of Pax7, Myf5 and Myod in proliferating C2C12 myoblasts in response to 
releasate treatment may be part of a coordinated response of myogenic regulatory factors 
that are known to promote myogenic population expansion 51.  This is in line with previous 
evidence showing failure to withdraw from the cell cycle and commit to differentiation in 
response to releasate use 24. Impaired Igf1 mRNA levels followed by unchanged mRNA and 
protein levels of IGF1Rα indicate that the effect of releasate on proliferating myoblasts is not 
mediated by IGF1. IGF1 is known to increase embryonic myoblast proliferation, but Igf1 
mRNA levels tend to be higher during myogenic differentiation46, 52. Increased mRNA levels 
of Prmt1 in response to releasate administration are in line with previous data reporting that 
arginine methylation by Prmt1 regulates muscle stem cell fate and it is important for 
myoblast fusion 53. Taken together, these data suggest that the observed effects on 
myoblast proliferation by platelet releasate may be at least in part mediated by the PDGF 
and VEGF growth factors.  
 
Given that Ngf has been shown previously to affect myogenic cell proliferation and 
differentiation and its expression is induced by platelet-rich plasma, we sought to determine 
whether platelet releasate affects neurotrophic growth factors (e.g. Ngf, Bdnf, Ntf-3, TrkA, 
TrkB and TrkC) gene expression in proliferating myoblasts 54, 55. Our data suggest that 
administration of releasate on proliferating myoblasts does not upregulate the gene 
expression of neurotrophic growth factors. However, one has to bear in mind that 
neurotrophic factors and their receptors are more important for myogenic differentiation and 
their expression patterns in myotubes in response to platelet releasate remains to be 
established. 
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By using a multiplex immunoassay we quantified several growth factors in human platelet 
releasate in response to known platelet agonists (i.e. TRAP6 and collagen). The heatmap of 
those factors suggests that their amount increases several-fold in platelet releasate resulting 
in two clusters of moderate and higher intensity respectively. Of note, the factors SCF, FGF-
β, HGF, HER2, Follistatin, VEGFR-1, EGFR, PDGF-AB and PDGF-BB (known to regulate 
proliferation 47, 48, 56-63) and VEGFR-2, IL-6, TIE-2 and HB-EGF (known to induce 
differentiation 61, 64-67) showed a 4-20-fold increase in the TRAP6-activated platelet releasate 
as compared to unstimulated platelets. EGF, FGF, VEGF and PDGF-BB have been shown 
to promote myoblast proliferation and consistently inhibit myogenic differentiation, while 
VEGFR2 expression is increased during differentiation48, 57, 61, 63, 68, 69. Moreover, SCF 
increases skeletal muscle stem cell number, IL-6 regulates myoblast proliferation and 
migration, while TNF-α inhibits myogenic differentiation in C2C12 cells through NF-κΒ and 
promotes myotube atrophy56, 64. Conversely, IGFBP-1, Angiopoietin-2and uPA have been 
shown to promote myogenic differentiation57, 70, 71. Of note, we cannot rule out that other 
growth factors (not included in the Bioplex kits used in this study) contained in the platelet 
releasate may potentially affect myogenesis. Taken together these data suggest the 
numerous growth factors, cell cycle regulators and transcription factors present in platelet 
releasate can be used to promote skeletal myogenesis. 
 
We next aimed to determine the role of PDGF and VEGF contained in the human platelet 
releasate in skeletal myogenesis. For this reason, we cultured C2C12 myoblasts with 
releasate and administered either a PDGFR or VEGFR known inhibitor 72, 73. Our data show 
a dose-dependent attenuation of myoblast proliferation for both inhibitors used separately, 
independent of the use of platelet releasate. These findings suggest that the powerful 
proliferative effect of platelet releasate on C2C12 myoblasts is, at least in part, mediated 
through PDGF and VEGF signalling. The proliferative effect of releasate is abolished by the 
highest dosage of PDGF or VEGF inhibitors. This may possibly be due to a crosstalk with 
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other growth factor receptors present in the releasate such as EGFR when used in high 
concentrations 74. This notion is strengthened by previous studies showing that PDGF/VEGF 
inhibition resulted in diminished myoblast proliferation and recombinant PDGFs improved 
skeletal muscle recovery after injury 20, 31, 47-50, 61, 75, 76.  
 
In contrast to myoblast proliferation, the use of platelet releasate during myogenic 
differentiation seems to be more complex. We show here that, on one hand, treatment of 
myotubes with releasate during terminal differentiation promotes myogenic differentiation 
(i.e. myogenin+ve cells and myotube number). On the other hand, administration of platelet 
releasate during both proliferation and differentiation of C2C12 myoblasts results in 
attenuated differentiation based on largely impaired Myogenin, Mhc1, Mhc2a, Mhc2b, Acta1, 
Tmem8c, Bex1, Igf-1 mRNA, myogenin protein expression, myotube number, myofusion 
index, myotube length and thickness, which is in line with recent studies using platelet-rich 
plasma 3, 22, 40. This is indicative of a failure to withdraw from the cell cycle, supported by the 
increased nuclei number (Figure 5A). Importantly, we provide evidence that platelet 
releasate is beneficial for myogenic differentiation leading to higher myogenin expression 
and larger myotubes, when it is administered after the early differentiation phase, where 
myoblast fusion into myotubes has started. Taken together, these data suggest that the 
timing of application of releasate to C2C12 myoblasts or myotubes is crucial and may 
account for discrepancies in the literature over whether releasate hampers or improves 
differentiation 17, 21, 44. 
 
Similar to myoblast proliferation, inhibition of PDGFR and VEGFR resulted in attenuated 
C2C12 myotube differentiation as shown by impaired myogenin expression and myotube 
number independent of releasate administration. This finding highlights the importance of 
PDGF and VEGF during myogenic differentiation. Previous research data suggest that 
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VEGF is important for myogenin expression as well as myoblast and myotube number 31, 69. 
Moreover, addition of PDGF-BB to myoblasts inhibits differentiation 32, 47, 48, 76. Of note, the 
myotube fusion index did not significantly differ amongst groups, indicating proliferation 
factors may be necessary for proper differentiation capacity and that lower total nuclei 
number may be accountable for the attenuated differentiation. Therefore, it appears that 
PDGF plays an important role during myoblast differentiation, which is in line with previous 
evidence that PDGFR inhibition decreases muscle mass 75.  
 
Collectively, we have shown so far that platelet releasate is capable of promoting myoblast 
proliferation and exhibits opposing effects on myogenic differentiation dependent on the time 
of application. We have also highlighted the important role of PDGF and VEGF for both 
myogenic proliferation and differentiation. This is important since PDGF and VEGF 
pathways interact through the Akt/mTOR pathway to induce skeletal muscle stem cell 
proliferation 49, 77, 78. In order to determine the effect of platelet releasate on muscle stem cell 
proliferation and differentiation profiles we used murine single muscle fibres in culture. We 
show here for first time that platelet releasate administration on single myofibres results in 
significant increase of Pax7-/MyoD+ muscle stem cells in a dose-dependent manner. These 
findings depict an increased commitment of proliferating muscle stem cells to differentiation 
as shown by MyoD+ve cells per total myonuclear number (i.e MyoD+/DAPI/fibre). The 
increase in committed muscle stem cells to differentiation in response to platelet releasate is 
evident for both serum free and standard fibre growth conditions, indicating that releasate 
may act as an appropriate substitute for the regular fibre growth medium. To this end, 
several studies have aimed to replace bovine serum by autologous platelet-based 
applications 20, 40. 
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Although upregulation of MyoD mRNA and protein in rat skeletal muscle stem cells by PRP 
has been shown previously on muscle sections, we provide here evidence that this is taking 
place with the concomitant downregulation of Pax7 which results in higher number of stem 
cells following the differentiation pathway to support myofibre regeneration 44, 45. Importantly, 
the effect of platelet releasate on MyoD is reversed by PDGFR and VEGFR inhibition, 
indicating a possible crosstalk between these factors. Indeed, addition of PDGF-BB 
decreases myoblast fusion, however it upregulates MyoD during myogenesis 32. 
Interestingly, application of platelet releasate resulted in a robust increase of Cyclin D1 and 
Scrib expression on muscle stem cells. Cyclin D1 driven by platelet releasate is known to 
regulate the cell cycle and is important for cell proliferation 24. Most importantly, Scrib is a 
significant regulator of myogenic progression after commitment to differentiation that dictates 
muscle stem cell fate and is indispensable for muscle repair 35.  
 
It has been claimed that the beneficial effects of platelet rich plasma on myogenesis can be 
brought about by the plasma per se 3. However, this possibility can be ruled out, since our 
data indicate that the use of platelet poor plasma does not mimic the findings on muscle 
stem cells observed with platelet releasate. Beyond that, platelet preparations were 
conducted with washed platelets in modified tyroid’s buffer and not plasma in this study.  
 
Despite previous evidence on compromised myogenic differentiation in response to PDGF 
administration, we found that platelet releasate was beneficial for muscle stem cell 
differentiation 32. In particular, we report that platelet releasate on single muscle fibres leads 
to significantly higher expression levels of Myogenin in differentiated muscle stem cells, 
significantly higher stem cell progeny and total stem cell numbers as well as number of stem 
cell clusters per fibre. Further to this, isolated primary skeletal muscle stem cells have an 
increased number, fusion index and myotube number when co-cultured with platelet 
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releasate and growth medium simultaneously; mitigating the negative effects that releasate 
has on differentiation alone. Altogether these findings provide novel evidence on a powerful 
effect of platelet releasate on muscle stem cell proliferation and commitment to 
differentiation through the PDGF/VEGF-Cyclin D1-MyoD-Scrib-Myogenin axis (Figure 10D). 
 
In order to obtain insights in the metabolic homeostasis of proliferating cells exposed to 
platelet releasate, we measured the oxygen consumption rate at the cellular level. We found 
that administration of releasate resulted in significantly higher spare oxidative capacity in 
isolated muscle stem cells under either serum free or serum rich conditions. This finding 
indicates that platelet releasate may alter metabolic homeostasis of muscle stem cells, 
which is important for myogenesis and most importantly for muscle regeneration. This notion 
is supported by previous studies showing that cardiac myoblasts (i.e. H9C2 cells) had an 
increased respiratory reserve capacity in response to platelet-rich plasma 37. In the current 
study, platelet releasate did not upregulate the OCR of C2C12 myoblasts under serum-rich 
conditions, as opposed to primary murine stem cells. A possible explanation of this finding 
may originate in the recently described role of MyoD in regulating skeletal muscle oxidative 
metabolism with implications for energy availability and muscle contraction79. Evidence also 
suggests that reactive oxygen species (ROS) are essential for activating several growth 
factors including PDGFs 80. Increased ROS production may overwhelm the antioxidant 
capacity of the cell resulting in oxidative stress. It can be speculated that the increased 
mRNA levels of DNA repair enzymes (i.e. Ogg1, Gadd45g and Parp1) in response to 
releasate treatment reported in this study may be part of a cellular response to the enhanced 
energetic state and potentially increased stress during accelerated myoblast proliferation. 
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Skeletal muscle regeneration following acute damage is a process that this reliant on a 
number of cell types that coordinate their activity to reconstitute a working tissue 81. This 
includes not only the resident stem cell population (i.e. satellite cells), which regenerate most 
if not all the muscle cells that eventually fuse to form muscle fibres but also macrophages 
and angioblasts 82-84. Here we show that platelet releasate promotes muscle regeneration 
following cardiotoxin injection evidenced the presence of larger newly formed muscle fibres. 
This outcome is in keeping with our in-vitro data in this paper showing that platelet releasate 
impacts on the proliferation and differentiation of myoblasts. Herein the accelerated 
regeneration is postulated to be a consequence of direct impact of the release on satellite 
cells. An additional possibility is that the angiogenic factors in the releasate could act on 
satellite cells indirectly so that that firstly promote angiogenesis in the regenerating tissue 
which then impacts on the activity of satellite cells. Indeed, angiogenesis is a major factor in 
muscle regeneration and can even compensate to a large decrease in muscle stem cells 
and still deliver robust regeneration 85. Finally, we show that the number of dying fibres and 
their size (an indicator of the clearance process) was greatly reduced by platelet releasate, a 
process controlled by macrophages. This may imply a role for the platelet releasate in 
controlling the pro-inflammatory/anti-inflammatory properties of macrophages. This could be 
of particular importance to setting of chronic muscle damage in a clinical context (such as 
Duchenne Muscular Dystrophy) in which the inflammatory process induces fibrosis and 
attenuates muscle regeneration 86. 
 
In conclusion, the present study provided evidence that methodological variability may 
account for discrepancies among studies on the role of platelet releasate in skeletal muscle 
regeneration. Platelet releasate promotes myoblast proliferation and terminal differentiation 
both in vitro and ex vivo. However, the timing of releasate application appears to be critical 
due to the inhibitory role of releasate on myoblast fusion as shown here and elsewhere 40. 
Most importantly, we showed for the first time that platelet releasate increases muscle stem 
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cell commitment to differentiation and promotes skeletal myogenesis through the 
PDGF/VEGF-Cyclin D1-MyoD-Scrib-Myogenin axis and accelerates skeletal muscle 
regeneration after acute injury. Collectively, the present findings can be exploited in future 
studies to pinpoint the role of platelets as biomaterials in skeletal muscle regeneration. 
 
Methods 
Ethics statement. The study was approved by the local Ethics Committee of the University. 
The animal experiments were performed under a project license from the United Kingdom 
Home Office in agreement with the revised Animals (Scientific Procedures) Act 1986 and the 
European Convention for the Protection of Vertebrate Animals used for Experimental and 
other Scientific Purposes' (Council of Europe No 123, Strasbourg 1985). Blood sampling 
from healthy human volunteers was performed with their written informed consent and was 
approved by the University’s Ethics Committee.  
 
Preparation of platelet releasate. Human platelet releasate (R) was prepared in acid 
citrate dextrose (ACD) to whole blood at a ratio of 1:5, centrifuged at 190g for 15 minutes 
followed by PRP collection and inactivation of platelets using prostaglandin I2 (534nM; 
Cayman Chemical). The PRP was then centrifuged in a swing-out rotor at 800g for 12 
minutes and the platelet-poor plasma (PPP) supernatant was then removed. Modified 
Tyrode’s buffer (NaCl, HEPES, NaH2PO4, NaHCO3, KCl, MgCl2 and D-Glucose) was used 
to re-suspend the platelet pellet to a concentration of 2.5x108 platelets mL-1 (unless 
otherwise stated) using a cell counter (Beckman Coulter; Z1-Series Coulter® Particle 
Counter). The platelet preparation was activated using a PAR1 agonist (TRAP6; 20μM; 
AnaSpec; cat. AS-60679), thrombin (0.05-0.1 NIH Units mL-1; Sigma Aldrich; cat.9002-04-4), 
or collagen (10μg mL-1; BioData; cat. 101562), in an aggregometer (CHRONO-LOG® Model 
490 4+4 Optical Aggregation System, USA). Alternatively, after counting and re-suspending 
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in modified Tyrode’s buffer, platelets were sonicated for 5 minutes using a 0.5 cycle at a 
gradually increasing amplitude of 60–100% (Hielscher Ultrasonic Processor - UP200S). 
Platelets were centrifuged at 9500g for 10 minutes, unless otherwise stated (see S. Figure 
1), and the releasate supernatant was aliquoted and stored at -80 °C until further use. 
 
Mouse platelets were prepared with 200μL ACD in a 1mL syringe & 25-gauge needle, gently 
mixed before transferring to 500μL modified Tyrode’s buffer with 500μL ACD, per mouse, 
and centrifuge in a swing-out rotor at 100g for 5 minutes with no breaks. The PRP 
supernatant was then transferred using a Pasteur pipette to a clean Eppendorf tube and 
centrifuged at 800g for 5 minutes with no breaks. The platelet-poor plasma was discarded 
and platelets were resuspended in modified Tyrode’s buffer to a concentration of 2.5x108 
platelets mL-1 using a Beckman Coulter particle counter. Collagen (10μg mL-1) was used to 
activate the platelets in an aggregometer for 5 minutes at 37ºC (reaching > 80% 
aggregation) before centrifuging at 9500g and storing releasates at -80 °C.  
 
Cell cultures and treatments. Murine C2C12 skeletal myoblasts (American Type Culture 
Collection, VA) were cultured in growth medium (GM); Dulbecco’s Modified Eagle’s Medium 
(DMEM; HyClone (High glucose, no sodium pyruvate)) supplemented with 10% foetal bovine 
serum (FBS) (Sigma-Aldrich), 1% penicillin/streptomycin (PS; Sigma-Aldrich) and 0.1% 
amphotericin B (AB; Sigma-Aldrich) at 37 °C in a humidified atmosphere of 5% CO2. To 
induce differentiation, C2C12 cells were cultured in GM until reaching 80% confluence 
before switching to differentiation media (DM), containing DMEM plus 2% horse serum (HS; 
Gibco) 1% PS and 0.1% AB for either 6, 9 or 12 days. Releasate was added either once 
during proliferation at time-point 0, or at every media change (either every 12 hours or 24 
hours depending on the experiment) during differentiation, unless otherwise stated. 
Inhibitors were added during DM media changes when indicated using 5μM PDGFR Inhibitor 
or a 130nM VEGFR Inhibitor. The myofusion index was calculated as myogenin+ve cells per 
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myotube (with a minimum threshold of 3 nuclei per myotube) divided by DAPI-stained cells 
as a percentage. For proliferation in all experimental groups, unless otherwise stated, 
C2C12 cells were cultured in serum free (SF) conditions (DMEM, 1% PS and 0.1% AB). 
Inhibitors used for proliferation and differentiation experiments were VEGFR Inhibitor (AAL-
993; 23nM, 130nM or 1.30μM, Merck) and PDGFR Inhibitor (Tyrphostin AG 1295 [AG-1295]; 
250nM, 500nM or 5μM, Santa Cruz). 
 
Cell proliferation and viability analysis. C2C12 myoblast cell proliferation was also 
evaluated by the pyrimidine analogue EdU incorporation assay using the fluorescent Click-
iT® EdU Cell Proliferation Assay (Invitrogen, Life Technologies, Grand Island, NY, USA) 
according to the manufacturer’s instructions. Proliferating cells were measured as EdU 
divided by DAPI (4',6-diamidino-2-phenylindol-stained (Dako))-stained nuclei as a 
percentage. Cellular viability was assessed by seeding 50,000 C2C12 cells in a 35mm petri 
dish for 24 hours in either serum-free, 10% FBS growth medium, 10% releasate or 10% FBS 
growth medium plus 10% releasate, and counting the ratio of live to dead cells using trypan 
blue. 
 
Single fibre isolation and culture. For single-fibre culture, murine C57Bl/6J single fibres 
were isolated from the extensor digitorum longus muscle (EDL). Limb muscles were 
dissected and subjected to collagenase (0.2%; Sigma Aldrich; cat. C2674) digestion for 3-4 
hours at 37 °C and 5% CO2 as described previously 87. The digested muscle was then 
gently triturated with a Pasteur pipette. Fibres were then cultured for 48 and 72 hours in 
single fibre media (FM; 10% horse serum, 0.5% chick embryo extract), or serum free media 
(SF) with the addition of 10% releasate (R) 3 times during culture every 16 hours (unless 
otherwise stated). Fibres were stained for mouse monoclonal anti-Pax7 (1:200, Santa Cruz; 
cat. sc-81648), rabbit polyclonal anti-MyoD (1:200; Santa Cruz; cat. sc-760) and rabbit 
polyclonal anti-Myogenin (Santa Cruz; cat. sc-576), or with anti-Cyclin D1 (1:200 Santa 
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Cruz; cat. sc-450) or Scrib (Santa Cruz; cat. sc-374139) and with DAPI. The commitment 
index was calculated as MyoD-stained muscle stem cells divided by DAPI-stained cells as a 
percentage. PDGF and VEGF were inhibited in the myofibres using either a 5μM PDGFR 
Inhibitor or a 130nM VEGFR Inhibitor.  
 
Satellite cell isolation from single fibres. For primary myoblasts, satellite cells (i.e. 
primary muscle stem cells) were derived from the EDL of wild-type C57Bl/6J mice. Briefly, 
limb muscles were dissected and subjected to 0.2% collagenase digestion for 4 hours at 37 
°C. The digested muscle was then gently transferred to 35mm petri dishes where the 
collagenase was removed. Single muscle fibres were isolated in SF culture medium, by 
means of a gentle mechanical trituration with a Pasteur pipette and then cultured for 72 h in 
Matrigel (1mg mL-1; Corning Matrigel; cat. 354234) –treated 6-well plates, at 37 °C in a 
humidified atmosphere of 5% CO2, in satellite proliferation media containing DMEM, 30% 
FBS, 1.5% chick embryo extract (C.E.E.) plus 1% penicillin-streptomycin. Next, the 
myofibres were removed and the satellite cells were cultured as per experimental conditions. 
Differentiation of primary satellite cells (stem cells) was achieved through culturing for 3 days 
in appropriate proliferation medium as per experimental condition before switching to 
differentiation medium (5% Horse Serum, 0.5% C.E.E., 1% P.S. and 0.1% A.B.) for a further 
5 days. 
 
Immunohistochemistry. C2C12 cells or primary muscle stem cells as appropriate were 
seeded on coverslips in 1mL of media in 24-well plates (Corning® Costar® TC-Treated 24-
Well Plates). Media was removed at the end of experiments with 4% paraformaldehyde 
added for 15 minutes, followed by two washes in phosphate-buffered saline. 
Permeabilisation buffer was then added for 20 minutes followed by two washes in wash 
buffer before applying onto optical slides. Primary antibodies for anti-Pax7 (Santa Cruz, cat. 
Sc-81648), anti-MyoD (Santa Cruz; cat. Sc-760), anti-Myogenin (Santa Cruz; cat. sc-52903), 
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mouse monoclonal anti-IGF-1Rα (Santa Cruz; cat. sc-271606), anti-PDGF B (Santa Cruz; 
cat. sc-365805), anti-VEGF (Santa Cruz; cat. sc-7269), anti-Ki-67 (ThermoFisher. Cat. 14-
5698-80), anti-myosin heavy chain 3 (Santa Cruz; cat. sc-53091), anti-Cyclin D1 (Santa 
Cruz; cat. sc-450) or anti-Scrib (Santa Cruz; cat. sc-374139) were added (1:200 in wash 
buffer) overnight. Primary antibodies were removed with 3 washes in wash buffer, followed 
by addition of secondary antibodies (Alexa fluor 488 Goat-anti-mouse; Life Technologies; 
cat. A11029 or Alexa fluor 594 Goat-anti-rabbit; Life Technologies; cat. A11037) in wash 
buffer (1:200). Cells were measured by the intensity of fluorescence per cell divided by 
DAPI-stained nuclei as a percentage.  
 
Platelet releasate growth factor multiplex immunoassay. Growth factors contained in the 
platelet releasate were measured by using high-performance multiplex immunoassays with 
the Bio-Plex Pro™ Human Cancer Biomarker Panel 1 and 2, (BioRad, UK, Cat. 171AC500M 
and 171AC600M respectively). This array system includes a blend of magnetic bead-based 
assays for a number of biomarkers involved in cell division such as Angiopoietin-2, sCD40L, 
EGF, Endoglin, sFASL, HB-EGF, IGFBP-1, IL-6, IL-8, IL-18, PAI-1, PLGF, TGF-α, TNF-α, 
uPA, VEGF-A, VEGF-C, VEGF-D, sEGFR, FGF-basic, Follistatin, HGF, sHER-2/neu, sIL-
6Rα, PECAM-1, PDGF-AB/BB, SCF, sTIE-2, sVEGFR-1, sVEGFR-2 as defined in 
Supplementary Table 1. All the assays were performed using the Bio-Plex 200 system 
according to the manufacturers’ instructions. Heatmap of hierarchical clustering and principal 
component analysis of Bio-Plex data was performed on the Perseus software (version 
1.5.5.3). 
 
RNA extraction and real-time PCR analysis. Quantitative PCR was performed as 
described previously 88. In brief, 2.4x105 C2C12 myoblasts were seeded per well of a 6-well 
plate in SF with or without 10% platelet releasate. After 24 hours cells were harvested in 
TRIzol (AMRESCO RiboZol™ RNA Extraction Reagent) for RNA isolation and qPCR. Total 
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RNA was prepared using the EZNA Total RNA Kit I (Omega Biotek, USA). Total RNA (2 μg) 
was reverse-transcribed to cDNA with RevertAid H MinusFirst Strand cDNA synthesis kit 
(ThermoFisher Scientific, USA) and analysed by quantitative real-time RT-PCR on a 
StepOne Plus cycler (Applied Biosystems, UK), using the Applied Biosystems SYBRGreen 
PCR Master Mix (Thermo Fisher Scientific; cat. 4364344). Primers were designed using the 
software Primer Express 3.0 (Applied Biosystems, UK). Details of primers are given in 
Supplementary Table 2. Relative expression was calculated using the ΔΔCt method with 
normalisation to the reference genes encoding cyclophilin-B (Cyp) and hypoxanthine-
guanine phosphoribosyltransferase (Hprt) 89. mRNA levels of Vegfa165, Vegfr1, Igf-1, Igf-1r, 
Pdgfα, Pdgfrα, Pdgfβ, Pdgfrβ, Pax7, Myf5, Myod, Prmt1, Ogg1, Gadd45g, Parp1, Ngf, Bdnf, 
Ntf3, TrkA, TrkB and TrkC were measured in cell cultures treated with serum-free, platelet 
releasate, growth medium or growth medium and releasate for proliferation. Similarly, mRNA 
levels of Pax7, Myod, Pdgfβ, Vegfa165, Myogenin, Mhc1, Mhc2a, Mhc2b, Acta1, Tmem8c, 
Bex1 and Igf-1 for growth medium ± releasate followed by differentiation medium ± 
releasate.  
 
Seahorse XFp extracellular flux measurements. C2C12 myoblasts and isolated satellite 
cells were seeded at a density of 10,000 cells per well in 8-well XF plates. Cells were pre-
incubated under serum-free conditions or treated with 10% releasate, 10% FBS or 10% 
releasate plus 10% FBS for 24 hours. Prior to the experiment, sensor cartridges were 
hydrated with XF calibrate solution (pH 7.4), as instructed by the manufacturer’s instructions 
and incubated at 37 °C in a non-CO2 environment for 24 hours. The cell culture medium was 
replaced with assay medium containing 1mM sodium pyruvate and incubated for one hour in 
a non-CO2 incubator. Carbonyl cyanide 4- (trifluoromethoxy)phenylhydrazone (FCCP; 5 µM 
final concentration) and antimycin (2.5 µM final concentration) were diluted in the assay 
medium. The Seahorse XFp Analyzer (Seahorse Biosciences) was used to measure the 
oxygen consumption rate (OCR) in real time. Baseline measurements of OCR were taken 
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before sequential injection of FCCP and antimycin. After three basal assay cycles, FCCP 
was injected to measure maximal mitochondrial respiration by uncoupling ATP synthesis 
from electron transport followed by injections of antimycin to measure the non-mitochondrial 
respiratory rate. Data were normalised to protein levels (BCA; Pierce Biotechnology). 
 
In Vivo cardiotoxin-induced muscle injury.  On day 1, Crl:CD-1 mice (12 week old) were 
tail vein injected (IV) either with 100 µL platelet releasate or 100 µL PBS (n=5 per group). 30 
minutes later, mice were injected with a total of 30µL, 50µM Naja pallida cardiotoxin (CTX; 
Latoxan, Valence France) into the tibialis anterior (TA) muscle. 24 hours later (day 2), the 
mice received a second identical intravenous injection of either the platelet releasate or 
PBS.  At 5 days, mice were sacrificed, the TA muscles were collected, immediately frozen 
and 12µM cryo-sections were processed for immunohistochemistry. 
 
Statistical analysis. Data are reported as mean±SD. Cell culture experiments were 
conducted with n=3-9 technical replicates and n=2-3 independent experiments as indicated 
in figure legends. Statistical differences among experimental groups were determined by 
one-way ANOVA followed by the Tukey post-hoc test. Differences between two groups were 
detected by using Student’s t test. Statistical differences were considered as significant for 
p < 0.05. Statistical analysis was performed on the SPSS software (IBM SPSS Statistics 
version 24). 
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Figure legends 
Figure 1. The effect of platelet agonists and species-of-origin during releasate 
preparation on C2C12 myoblast proliferation. (A) A schematic depicting the methods of 
obtaining platelet releasate or platelet lysate. (B-C) Representative images and quantitative 
data for C2C12 myoblast proliferation (EdU) and nuclear staining (DAPI) by releasate from 
platelets activated with collagen, TRAP6 (a PAR1 agonist) or thrombin (x5 magnification, 
scale bar 200μm). Lysates from mechanically-activated platelets was achieved by sonication 
(S.L.). Control conditions included serum-free (SF) DMEM ± 10-20% FBS (GM). (D) Total 
protein concentrations (mg mL
-1
) for the 3 platelet releasates activated with different platelet 
agonists. (E) Dose-dependent effect of PAR1-activated platelet releasate (i.e. 10, 20, 30% 
v/v) on C2C12 myoblast proliferation after 24h. Representative images for proliferating 
C2C12 myoblasts (EdU) and total nuclear staining (DAPI); (x10 magnification, scale bar 
200μm). (F) Quantitative data on the effect of human (Human R; stimulated with PAR1) and 
mouse platelet releasate (Mouse R; stimulated with collagen) on C2C12 myoblast 
proliferation (EdU). Data are mean±SD (n=3/group, 3 independent experiments). Statistical 
analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test. Differences 
are *p<0.05, ***p<0.001 and #p<0.001 vs. every other group. 
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Figure 2. The effect of releasate from different platelet concentrations on C2C12 
myoblast proliferation and myoblast gene and protein expression patterns. (A) 
Representative images for C2C12 myoblast proliferation (EdU) and nuclear staining (DAPI) 
(x5 magnification, scale bar 200μm) in response to physiological (i.e. 2.5x108) and non-
physiological platelet concentrations. Quantitative data showed a significant effect of 
physiological platelet concentration on C2C12 myoblast proliferation that was comparable to 
10% FBS (GM) and supra-physiological platelet concentrations (i.e. 5-10x108). Control 
conditions included serum-free (SF) DMEM ± 10% FBS (GM). Data are mean±SD 
(n=3/group, 2 independent experiments). Statistical analysis was performed by one-way 
ANOVA followed by Tukey’s post hoc test. Statistically significant differences are ***p<0.001 
and # for p<0.001 compared to GM and 2.5-10x108 respectively. (B) Myoblast gene 
expression patterns using releasate from physiological platelet concentration (i.e. 2.5x108) 
by qPCR for Vegfa165, Vegfr1, Igf1, Igf1r, Pdgfα, Pdgfrα, Pdgfβ, Pdgfrβ, Pax7, Myf5, Myod 
and Prmt1 on 10% releasate vs. control (DMEM). Data are mean±SD (n=6/group). Statistical 
analysis was performed by unpaired Student’s t-tests. Differences are ***p<0.001, **p<0.01. 
(C) Immunohistochemical staining of PDGF B, VEGF or IGF-1Rα in C2C12 myoblasts 
cultured with SF, 10% FBS (GM) or 10% R for 24 hours; (x10 magnification, scale bar 
200μm, inlay images are x40 magnification with 20μm scale bars). Statistical analysis was 
performed by one-way ANOVA followed by Tukey’s post hoc test. Differences are *p<0.05, 
and **p<0.01 vs. the SF control group. 
 
Figure 3. Growth factors measured in platelet releasate. Human platelet suspensions 
were aggregated using either TRAP6 (a PAR1 agonist), or collagen, or were left 
unstimulated. Concentrations of specific analytes contained in BIOPLEX ONCO I and II 
panels were measured in platelet releasate. Platelets from n=6 independent donors were 
used in this assay. (A) Hierarchical clustering representing the average expression intensity 
of each analyte per condition (U, unstimulated; C, collagen; T, TRAP6). (B) Principal 
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Component Analysis (PCA) representing the distribution and grouping of samples 
considering the analytes measured as a whole. 
 
Figure 4. VEGFR and PDGFR inhibitors dose-dependently attenuate the effect of 
releasate on C2C12 myoblast proliferation. C2C12 cells were treated with either 10% 
FBS (GM) or 10% Releasate ± VEGFR Inhibitor (AAL-993; 23nM, 130nM or 1.30μM) or 10% 
releasate ± PDGFR Inhibitor (Tyrphostin AG 1295; [AG-1295] 250nM, 500nM or 5μM). 
Control conditions included serum-free (SF) DMEM ± 10% FBS (GM) or 10% Releasate (R). 
(A) Representative images for C2C12 myoblast proliferation (EdU) and nuclear staining (x5 
magnification, scale bar 200μm) (DAPI). (B) Quantitative data on the effect of VEGFR and 
PDGFR inhibition show a dose-dependent attenuation of myoblast proliferation with or 
without releasate treatment. Data are mean±SD (n=8/group, 2 independent experiments). 
Statistical analysis was performed by one-way ANOVA followed by Tukey’s post hoc test. 
Differences are *p<0.05, **p<0.01, ***p<0.001 and #p<0.05 vs. the SF (control) group, 
¥p<0.05 vs. the R group. 
 
Figure 5. Releasate causes C2C12 myoblasts to fail exiting the proliferative phase 
dependent on the timing of application. (A) Schematic depicting the experimental setup; 
C2C12 myoblasts were seeded with either 10% releasate (R) and/or 10% FBS (GM) for 2 
days followed by adding differentiation medium (DM; 2% horse serum) every 0.5 days ±R. 
for a total of 9 days culture. Representative images for Myogenin and DAPI (x5 
magnification, scale bar 200μm). The myotube fusion index was calculated by Myogenin+ve 
nuclei in myotubes/ DAPI as a percentage. Outcome measures include the nuclei number, 
number of Myogenin+ve nuclei, myotubes (n=3 nuclei/ myotube), myotube thickness and 
length (μm). Gene expression for Pax7, Myod, Pdgfβ, Vegf165α, Myogenin, Mhc1, Mhc2a, 
Mhc2b, Acta1, Tmem8c, Bex1 and Igf-1 was measured by qPCR for these 3 groups (i.e. 
GM;DM, GM+R;DM and GM+R;DM+R). (B) Schematic depicting experimental setup, as well 
as representative images (x5 magnification, scale bar 200μm). C2C12 cells were seeded 
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with 10% FBS (GM) (GM;DM, GM;DM+R.Day 5-12). For the next 8 days, DM was added 
daily for every group and releasate added daily with each media change on day 5-12. 
Outcome measures include the number of myotubes, nuclei, myonuclei, myotube thickness 
and length (μm). Data are mean±SD (n=9/group, 3 independent experiments). Statistical 
analysis was performed by one-way ANOVA followed by Tukey’s post hoc test. Differences 
are *p<0.05, **p<0.01, ***p<0.001, vs. the positive control (GM:DM). 
 
Figure 6. PDGFR and VEGFR Inhibitors have a detrimental effect on nuclei number, 
myogenin expression and myotube number during differentiation. (A) Schematic 
depicting the experimental setup; C2C12 cells were seeded with either 10% FBS (GM), 10% 
Releasate (R).  After 1 Day of proliferation, media was changed to 2% horse serum (DM) 
with or without a 5μM PDGFR Inhibitor (AG-1295) or a 130nM VEGFR Inhibitor (AAL-993). 
Media was changed daily with inhibitors added on each change. Releasate was added on 
day 5 only, 1 day before experimental termination (GM;DM+R D.5). (B) PDGFR and VEGFR 
inhibition in control cultures (GM:DM). (C) PDGFR and VEGFR inhibition in cultures 
supplemented with releasate on day 5 (GM:DM+R D5 only). (B-C) Representative images 
for myogenin and DAPI. The myofusion index was calculated by myotube nuceli/ total DAPI 
as a percentage. Outcome measures include the number of nuclei, myogenin+ve nuclei, 
myotubes, myotube thickness and length (μm). Data are mean±SD (n=3/group, 2 
independent experiments). Statistical analysis was performed by one-way ANOVA followed 
by Tukey’s post hoc test. Differences are *p<0.05, **p<0.01, ***p<0.001 vs. the positive 
control (GM;DM).  
 
Figure 7. Platelet releasate increases myofibre stem cell commitment to differentiation 
through VEGF and PDGF in a dose-dependent manner. Murine C57Bl/6J single fibres 
were isolated from the extensor digitorum longus muscle (EDL) for 48 hours culture in single 
fibre media (FM), or serum free media (SF) with the addition of releasate (R) either x1 or x2 
(every 24 hours) or x3 (every 16 hours) media changes. (A-B) The percentage of muscle 
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stem cells/ fibre expressing myogenic regulatory factors (MRFs) Pax7+ve/MyoD+ve (White 
arrows) for cell activation, Pax7-ve/MyoD+ve (Red arrows) for commitment to differentiation 
and Pax7+ve/MyoD-ve (Green arrows) for quiescence (n=10 mice, 17 EDL muscles; 50-130 
fibres quantified per condition (x40 magnification, scale bar 20μm). (C) Percent of Pax7-
ve/MyoD+ve cells per total nuclei (DAPI) per fibre. (D) Murine C57BL6 single fibres were 
isolated from the EDL for 48 hours culture in FM or serum free media (SF) with the addition 
of 10% releasate (R) (every 16 hours) ± PDGFR (AG-1295) or VEGFR (AAL-993) Inhibitors. 
Quantitative data representing the percentage of muscle stem cell expression per fibre 
expressing MRFs (upper graph) and total muscle stem cell number (lower graph). Statistical 
analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test. Differences 
are *p<0.05, **p<0.01, ***p<0.001 vs. every other group for Pax7-ve/MyoD+ve cells, and 
#p<0.05 for Pax7+ve/MyoD-ve cells vs. every other group. 
 
Figure 8. Platelet releasate causes an increase in muscle stem cell proliferation and 
regulates cell fate through upregulation of Cyclin D1 and Scrib respectively. (A) 
Representative images from single fibres stained for Cyclin D1, Scrib, MyoD and DAPI (x40 
magnification, scale bar 20μm). (B) The relative expression (%) of MyoD, Cyclin D1 and 
Scrib and DAPI for nuclei staining on muscle stem cells. Results are shown for serum-free 
(SF), Fibre Medium (10% HS; FM), 10% Releasate (R) and FM+R. (C) Cyclin D1 and Scrib 
immunohistochemical expression in C2C12 as a percentage per DAPI for serum-free, 10% 
FBS growth medium, and 10% releasate conditions. (D) Total muscle stem cell number per 
condition at time-point 48 hours of single fibre isolation ex vivo. Statistical analysis was 
performed by one-way ANOVA followed by Tukey’s post-hoc test. Differences are *p<0.05, 
**p<0.01, ***p<0.001 and #p<0.01 vs. every other group. Differences for (B) refer to Cyclin 
D1/MyoD (double staining) ***p<0.001.  
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Figure 9. Releasate increases muscle stem cell progeny without affecting the relative 
expression pattern (%) after 72 hours in serum-free conditions. Male murine C57BL6 
single fibres were isolated from the extensor digitorum longus muscle for 72 hours culture in 
single fibre media (FM), or serum free media (SF) with or without the addition of releasate 
(R) every 24 hours. (A) Representative images for Pax7 and Myogenin staining (x40 
magnification, scale bar 20μm).The percentage of muscle stem (satellite) cells per fibre 
expressing Pax7+ve/Myogenin+ve (white arrows), Pax7-ve/Myogenin+ve (red arrows) for 
differentiating cells and Pax7+ve/Myogenin-ve (green arrows) for return to quiescence. (B) 
Outcome measures include satellite cell expression pattern (number and percentage per 
fibre), total number of satellite cells and number of clusters per fibre. (C) Standardised rank 
of the satellite cell progeny for SF, FM and R conditions for T48 and T72 hours. Regression 
analysis correlating T48 and T72 hour satellite cell progeny numbers revealed different 
gradient values (i.e. slopes) indicative of the satellite cell proliferation rates. Statistical 
analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test. Differences 
are *p<0.05, **p<0.01, and ***p<0.001 vs. the SF control group. 
 
Figure 10. Platelet releasate affects myoblast or muscle stem cell metabolism. (A) 
C2C12 myoblasts were seeded in seahorse plates for 24h in either serum free (SF) 10% 
releasate (R), or 10% FBS growth medium (GM) 10% R. (B) Muscle stem cells were 
isolated from EDL (n=8) single fibres from male C57BL6 mice and cultured for 72 hours in 
growth media containing 30% FBS and 1.5% chick embryo extract. Cells were then 
transferred to a seahorse plate in either growth media with GM, R or GM+R. The OCR was 
measured in response to FCCP and antimycin injections. (C) Isolated primary skeletal 
muscle stem cells from biceps brachii (BB) of C57Bl/6J mice (WT) cultured for 3 days in 
growth media (GM) or growth media plus releasate (GM+R), before changing to 
differentiation media for an additional 5 days with or without daily addition of 10% releasate. 
Representative data outcomes include cell number, myonuclei number, myofusion index and 
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myotube number. (D) Schematic highlighting the beneficial effect of platelet releasate on 
muscle stem cell proliferation and differentiation. Our findings suggest that platelet releasate 
increases muscle stem cell commitment to differentiation and promotes skeletal myogenesis 
through the PDGF/VEGF-Cyclin D1-MyoD-Scrib-Myogenin axis. Data are mean±SD. 
Statistical analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test. 
Differences are *p<0.05, **p<0.01, ***p<0.001 for either GM vs. GM+R or SF vs. R and 
#p<0.001 vs. every other group.  
 
Figure 11. Platelet releasate accelerates skeletal muscle regeneration of tibialis 
anterior in vivo. (A-B) Representative images for the identification of regenerating muscle 
fibres (through the expression of embryonic myosin heavy chain (eMHC), and damaged and 
dying fibres (identified through the presence of IgG inside muscle fibres on day 5 after 
cardiotoxin injury and platelet releasate treatment. Scale bar: 100μm. Data are mean ±SD. 
Statistical analysis was performed by Student’s t-test. Differences are ***p<0.001 between 
the cardiotoxin (CTX) and the releasate (CTX + Releasate) group. 
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